Bouvel Investment Partners LLC Purchases 67 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Bouvel Investment Partners LLC increased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,950 shares of the medical equipment provider’s stock after purchasing an additional 67 shares during the quarter. Intuitive Surgical makes up 2.5% of Bouvel Investment Partners LLC’s portfolio, making the stock its 8th biggest position. Bouvel Investment Partners LLC’s holdings in Intuitive Surgical were worth $6,853,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ridgewood Investments LLC acquired a new stake in shares of Intuitive Surgical during the second quarter worth $26,000. Godsey & Gibb Inc. boosted its holdings in Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares during the last quarter. Creekmur Asset Management LLC grew its position in shares of Intuitive Surgical by 200.0% during the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 42 shares during the period. LGT Financial Advisors LLC raised its position in shares of Intuitive Surgical by 415.4% in the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 54 shares during the period. Finally, Delos Wealth Advisors LLC raised its position in shares of Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the period. 83.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Intuitive Surgical news, insider Jamie Samath sold 269 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $539.89, for a total transaction of $145,230.41. Following the completion of the sale, the insider now owns 8,757 shares of the company’s stock, valued at $4,727,816.73. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, insider Jamie Samath sold 269 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $539.89, for a total transaction of $145,230.41. Following the completion of the sale, the insider now directly owns 8,757 shares in the company, valued at $4,727,816.73. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 91,178 shares of company stock valued at $45,897,071. 0.90% of the stock is owned by insiders.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $536.69 on Thursday. The business has a 50-day moving average of $495.85 and a 200-day moving average of $455.08. The stock has a market capitalization of $191.16 billion, a price-to-earnings ratio of 86.28, a PEG ratio of 5.28 and a beta of 1.39. Intuitive Surgical, Inc. has a fifty-two week low of $287.98 and a fifty-two week high of $542.59.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 5.45 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ISRG shares. Raymond James lifted their price target on shares of Intuitive Surgical from $500.00 to $540.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Oppenheimer reiterated a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Stifel Nicolaus increased their price target on Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Robert W. Baird lifted their price objective on Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, JPMorgan Chase & Co. increased their target price on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $513.74.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.